4/26, 8:10 AM (Source: TeleTrader)
more TeleTrader news

AstraZeneca's EPS jump 75% in Q1 to $0.47

British-Swedish pharmaceutical company AstraZeneca plc posted earnings per share of $0.47 for the first quarter of 2019, marking a 75% jump year over year. Revenues for the first three months of this year totaled $5.49 billion, adding 6% on an annual basis and 11% at a constant currency exchange.

Reported operating profit jumped 58% to $1.1 billion while core operating profit surged 84% to reach $1.65 billion, the financial release from the company showed. The Reported Gross Margin was 79% in the quarter, two percentage points higher than in the same period a year ago, while Operating Margin advanced seven percentage points to 20% at the same time, according to the results published.

Chief executive officer of the company, Pascal Soriot, noted: "Emerging Markets, our largest sales region, delivered an outstanding performance with a 22% growth rate; all of its sub-regions grew strongly, including China at 28%. Our Core Operating Profit almost doubled, demonstrating strong operating-margin improvement. Together with this encouraging financial start to the year, our highly-productive and sustainable pipeline continued to deliver, notably with a regulatory approval for Lynparza in the EU for the treatment of metastatic breast cancer and approvals of Farxiga in type-1 diabetes."

Breaking the News / NI